Regeneron defends bid to challenge Merck in lung cancer

Regeneron is years behind cancer immunotherapy rivals like Merck & Co. and Bristol-Myers Squibb. But, in their usual brash fashion, company executives on Tuesday made the case for their drug Libtayo and a broader immuno-oncology strategy that's advanced eight other candidates across a range of tumor types.